文献速递临床试验与 GCP流行病学与生物统计

在马里1-11月龄婴儿中测试阿奇霉素群体给药对死亡率及其他结局的影响(LAKANA):整群随机、安慰剂对照、双盲、平行组、三臂临床试验的研究方案

Testing the effects of mass drug administration of azithromycin on mortality and other outcomes among 1-11-month-old infants in Mali (LAKANA): study protocol for a cluster-randomized, placebo-controlled, double-blinded, parallel-group, three-arm clinical trial.
PubMed 文献 · Trials · 2023-01-03

LAKANA试验是在马里高死亡率且疟疾全地方性流行、已有全国季节性疟疾化学预防规划的地区开展的整群随机、安慰剂对照、双盲、平行组、三臂临床试验,旨在评估对1-11月龄婴儿每年4剂或2剂阿奇霉素群体给药对死亡率和健康的影响。参试村按3:2:4随机分配至安慰剂组、4剂阿奇霉素组和2剂阿奇霉素组,主要结局为死亡率,并将在干预前后及给药与未给药者中密切监测抗菌药物耐药性。

要点

  • LAKANA为整群随机、安慰剂对照、双盲、三臂试验,参试村按3:2:4分配至安慰剂组、4剂阿奇霉素组和2剂阿奇霉素组。
  • 研究对象为马里1-11月龄(29-364天)婴儿,主要结局为死亡率,并监测抗菌药物耐药性。
  • 研究计划入组于2020年10月开始、2022年底完成,预计研究完成日期为2024年12月。

核心结论

  • 若LAKANA提供证据支持阿奇霉素群体给药带来死亡率获益,将显著增加马里及撒哈拉以南非洲其他地区成功促进儿童存活的选项。

研究设计与样本

  • LAKANA为整群随机、安慰剂对照、双盲、平行组、三臂临床试验,在马里高死亡率且疟疾全地方性流行、有全国季节性疟疾化学预防规划的地区开展。
  • 参试村(整群)按3:2:4比例随机分配至三组:安慰剂(对照)组、4剂阿奇霉素组、2剂阿奇霉素组。
  • 干预为对1-11月龄(29-364天)婴儿每年实施4轮或2轮阿奇霉素群体给药。
  • 主要结局为死亡率;部分村庄的子集还评估发病率、生长与营养状态、疟疾寄生虫血症与炎症、安全性(抗菌药物耐药性、不良事件与严重不良事件)及实施可行性、可接受性与经济性等结局。
  • 入组于2020年10月开始,计划2022年底完成,预计研究完成日期为2024年12月;试验注册号ClinicalTrials.gov NCT04424511,注册日期2020年6月11日。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文指出既往在马拉维、尼日尔和坦桑尼亚开展的大规模整群随机试验提示阿奇霉素效果因国家而异、可能在婴儿中更强、可能集中在治疗后前3个月内。
  • 原文指出另一项研究发现阿奇霉素与季节性疟疾化学预防同时给药时未见效果。
  • 原文指出鉴于观察到的异质性及其他共同干预可能的效应修饰,需要进一步试验以确定在其他环境中的效果及最有效的治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mass drug administration (MDA) of azithromycin (AZI) has been shown to reduce under-5 mortality in some but not all sub-Saharan African settings. A large-scale cluster-randomized trial conducted in Malawi, Niger, and Tanzania suggested that the effect differs by country, may be stronger in infants, and may be concentrated within the first 3 months after treatment. Another study found no effect when azithromycin was given concomitantly with seasonal malaria chemoprevention (SMC). Given the observed heterogeneity and possible effect modification by other co-interventions, further trials are needed to determine the efficacy in additional settings and to determine the most effective treatment regimen. METHODS: LAKANA stands for Large-scale Assessment of the Key health-promoting Activities of two New mass drug administration regimens with Azithromycin. The LAKANA trial is designed to address the mortality and health impacts of 4 or 2 annual rounds of azithromycin MDA delivered to 1-11-month-old (29-364 days) infants, in a high-mortality and malaria holoendemic Malian setting where there is a national SMC program. Participating villages (clusters) are randomly allocated in a ratio of 3:2:4 to three groups: placebo (control):4-dose AZI:2-dose AZI. The primary outcome measured is mortality. Antimicrobial resistance (AMR) will be monitored closely before, during, and after the intervention and both among those receiving and those not receiving MDA with the study drugs. Other outcomes, from a subset of villages, comprise efficacy outcomes related to morbidity, growth and nutritional status, outcomes related to the mechanism of azithromycin activity through measures of malaria parasitemia and inflammation, safety outcomes (AMR, adverse and serious adverse events), and outcomes related to the implementation of the intervention documenting feasibility, acceptability, and economic aspects. The enrolment commenced in October 2020 and is planned to be completed by the end of 2022. The expected date of study completion is December 2024. DISCUSSION: If LAKANA provides evidence in support of a positive mortality benefit resulting from azithromycin MDA, it will significantly contribute to the options for successfully promoting child survival in Mali, and elsewhere in sub-Saharan Africa. TRIAL REGISTRATION: ClinicalTrials.gov NCT04424511. Registered on 11 June 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Adubra L, Alber D, Ashorn P, et al. Testing the effects of mass drug administration of azithromycin on mortality and other outcomes among 1-11-month-old infants in Mali (LAKANA): study protocol for a cluster-randomized, placebo-controlled, double-blinded, parallel-group, three-arm clinical trial. Trials. 2023. PMID: 36597115. doi:10.1186/s13063-022-06966-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。